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BRIEF REPORT
Antiemetic use among pregnant women in the United States: the
escalating use of ondansetron
Lockwood G. Taylor1* , Steven T. Bird1, Leyla Sahin1, Melissa S. Tassinari1, Patty Greene1,
Marsha E. Reichman1, Susan E. Andrade2, Katherine Haffenreffer3 and Sengwee Toh3
1Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA
2Meyers Primary Care Institute (Fallon Community Health Plan, Reliant Medical Group, and University of Massachusetts Medical School),
Worcester, MA, USA
3Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
ABSTRACT
Purpose To examine ondansetron use in pregnancy in the context of other antiemetic use among a large insured United States population
of women delivering live births.
Methods We assessed ondansetron and other antiemetic use among pregnant women delivering live births between 2001 and 2015 in 15
data partners contributing data to the Mini-Sentinel Distributed Database. We identified live birth pregnancies using a validated algorithm,
and all forms of ondansetron and other available antiemetics were identified using National Drug Codes or procedure codes. We assessed the
prevalence of antiemetic use by trimester, calendar year, and formulation.
Results In over 2.3 million pregnancies, the prevalence of ondansetron, promethazine, metoclopramide, or doxylamine/pyridoxine use
anytime in pregnancy was 15.2, 10.3, 4.0, and 0.4%, respectively. Ondansetron use increased from <1% of pregnancies in 2001 to
22.2% in 2014, with much of the increase attributable to oral ondansetron beginning in 2006. Promethazine and metoclopramide use
increased modestly between 2001 (13.8%, 3.2%) and 2006 (16.0%, 6.0%) but decreased annually through 2014 (8.0%, 3.2%).
Doxylamine/pyridoxine, approved for management of nausea and vomiting in pregnancy in 2013, was used in 1.8% of pregnancies in
2014. For all antiemetics, use was highest in the first trimester.
Conclusions We observed a marked increase in ondansetron use by study year, prescribed to nearly one-quarter of insured pregnant
women in 2014, occurring in conjunction with decreased use of promethazine and metoclopramide. Given the widespread use of
ondansetron in pregnancy, data establishing product efficacy and methodologically rigorous evaluation of post-marketing safety are needed.
Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
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INTRODUCTION
Nausea and vomiting in pregnancy (NVP) affects up to
80% of pregnant women, predominantly between 5
and 18 weeks gestation.1 An extreme form of NVP,
hyperemesis gravidarum, presents as persistent
nausea and vomiting, dehydration, weight loss, and
electrolyte abnormalities.1 Hyperemesis gravidarum
occurs in <3% of pregnancies, can adversely affect
both the fetus and mother, and it is the most common
reason for first trimester hospitalization.2 A systematic
review found that women with hyperemesis
gravidarum have a higher incidence of low birth
weight, premature births, and small for gestational
age infants.3
Antiemetic pharmacotherapy has long since played
a role in NVP treatment. Metoclopramide, anticholin-
ergics, and 5-hydroxytryptamine-3 antagonist are pre-
scribed off-label for NVP; however, doxylamine/
pyridoxine (Diclegis), approved in 2013, is the only
medication approved for the treatment NVP.
Ondansetron is a 5-hydroxytryptamine-3 antagonist
widely used for the prevention of nausea and vomiting
*Correspondence to: L. G. Taylor, Center for Drug Evaluation and Research, US
Food and Drug Administration, 10903 New Hampshire Avenue, Bldg 22,
Rm2406, Silver Spring,MD20903,USA. E-mail: lockwood.taylor@fda.hhs.gov
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associated with chemotherapy, radiotherapy, and in
postoperative settings. While ondansetron is not
approved for NVP, it has been prescribed off-label
for the condition. Recent studies have suggested
possible ondansetron-associated birth defects with
use during the first trimester of pregnancy,4,5 but
evidence to date is limited and inconclusive. We
sought to evaluate the extent of ondansetron use in
pregnancy, in the context of other antiemetic use,




The Mini-Sentinel pilot was launched in 2009 by the
US Food and Drug Administration (FDA) to perform
active surveillance for medical product safety.6
Briefly, Mini-Sentinel consists of electronic healthcare
data from a distributed network of 18 data partners,
mostly large commercial health insurers, who contrib-
ute data using a common data model. The common
data model allows for standardized queries across data
partners and includes a robust data quality assurance
process.7 This analysis included the 15 data partners
(14 private [e.g., Aetna, Humana] and one public
insurer [Tennessee Medicaid]) that contributed data
on pregnancies including inpatient, outpatient, and
emergency room diagnoses and procedures, outpatient
pharmacy dispensing, and demographic and healthcare
enrollment between April 2001 and October 2015. Not
all data partners contributed data over the entire study
period, with more partners contributing data in more
recent years (Table S1).
Pregnancy identification
Pregnancies ending in live births among women aged
10 through 54 years at delivery were identified using
a validated algorithm based on International Classifi-
cation of Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) diagnosis and procedure codes.8 Eligible
women required continuous medical and pharmacy
healthcare enrollment for a minimum 480 days prior
to delivery admission to capture drug exposures during
and prior to pregnancy.
Drug exposure
Use of the following antiemetics among pregnant
women was identified using National Drug Codes:
dolasetron mesylate (injectable, oral), doxylamine
succinate/pyridoxine (oral), granisetron (injectable,
oral, transdermal), metoclopramide (injectable, oral),
ondansetron (injectable, oral), palonosetron (inject-
able), prochlorperazine (injectable, oral, rectal), and
promethazine (injectable, oral, rectal). Pregnant
women were considered exposed if they received at
least one antiemetic (dispensed or administered)
anytime during pregnancy. Trimesters were defined
as 0–90 days (first trimester), 91–180 days (second
trimester), and 181 through the delivery date (third
trimester).
Data analysis
Each site submitted aggregate-level data to the Mini-
Sentinel Operations Center to create overall estimates
of antiemetic use by formulation, trimester, maternal
age, and calendar year. Analyses of antiemetic use
by year excludes 2015 because this was a partial year
of data, and not all data partners contributed data for
this year at the time of the data pull. Trend analyses
evaluated the change in the percent utilization by
calendar year rather than the absolute number of users
per calendar year to account for the fact that not all
data partners contributed data over the entire study
period. Analyses were conducted using SAS 9.3
(Cary, North Carolina). No individual-level data were
transferred to the Mini-Sentinel Operations Center or
the US FDA. Mini-Sentinel projects are classified as
public health activities, and individual Institutional
Review Board approval was not required.9
RESULTS
The final sample consisted of 1 949 201 women
contributing 2 342 489 live birth pregnancies. Five
larger data partners contributed approximately 80%
of the data. Population characteristics are shown in
Table 1. Over half (54.9%) of the pregnancies were
in women at least 30 years of age (Table S2).
During the study period, prescription antiemetic use
occurred in 23.5% of pregnancies ending in a live birth.
Ondansetron was the most commonly used antiemetic
during pregnancy (15.2%), followed by promethazine
(10.3%) and metoclopramide (4.0%) (Table 1). For
all antiemetics, use was most common in the first
trimester and decreased throughout pregnancy.
Any antiemetic use increased from 17.0% of live
birth pregnancies in 2001 to 27.2% in 2014. Specifi-
cally, ondansetron use in pregnancy increased from
0.96% of pregnancies in 2001 to 22.2% of pregnancies
in 2014, with the most substantial increased trend
beginning in 2006 (Figure 1). The trend for
ondansetron was relatively similar across all data part-
ners contributing data to this analysis (data not
analysis of antiemetic use in pregnancy 593
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shown). Promethazine use increased modestly
between 2001 (13.8%) and 2006 (16.0%) but
decreased annually after 2006 to 8.0% in 2014. A
similar trend was observed with metoclopramide, with
the highest use in 2006 (6.0%), decreasing annually to
3.2% in 2014. Doxylamine/pyridoxine use increased
from <0.1% of pregnancies in 2013 to 1.8% in 2014.
Use of both oral and injectable forms of ondansetron
increased during the study period (Figure 1; dashed
lines). Oral ondansetron use accounted for much of
the overall increase in use from 2006 to 2014, during
which the prevalence increased six-fold from 3.1 to
19.7%, while the increase in the injectable form was
more modest (2006: 1.8%; 2014: 5.1%; some women
received both formulations).
DISCUSSION
Our data show ondansetron utilization during
pregnancy increased from approximately 1% of all
pregnancies in 2001 to nearly a quarter of pregnancies
in 2014. The increased trend for ondansetron was
observed across all data partners. The marked increase
in ondansetron use from 2006 to 2014 occurred in
conjunction with decreased use of promethazine and
metoclopramide; however, the increase in ondansetron
use was significantly higher than the decrease of the
latter antiemetics.
While the factors driving the dramatic increase in
ondansetron use are unclear, it may in part be explained
by the large number of approved generic applications
Table 1. Prevalence of antiemetic prescription among live birth pregnancies identified in the Mini-Sentinel Distributed Database, 2001–20151
Generic name2










Use in first, second,
and third trimester
No. pregnancies n = 2,342,489 n = 2,342,489 n = 2,342,489 n = 2,342,489 n = 2,341,9924 n = 2,341,9924
Any antiemetic 78 770 (3.36%) 550 335 (23.49%) 390 217 (16.66%) 265 820 (11.35%) 157 217 (6.71%) 52 453 (2.24%)
Dolasetron 346 (0.01%) 3155 (0.13%) 2167 (0.09%) 1568 (0.07%) 578 (0.02%) 165 (0.01%)
Doxylamine/Pyridoxine3 30 (0.00%) 8735 (0.37%) 6812 (0.29%) 5943 (0.25%) 1903 (0.08%) 1006 (0.04%)
Granisetron 161 (0.01%) 352 (0.02%) 163 (0.01%) 133 (0.01%) 123 (0.01%) 10 (0.00%)
Metoclopramide 9797 (0.42%) 93 481 (3.99%) 57 433 (2.45%) 38 868 (1.66%) 21 615 (0.92%) 2250 (0.10%)
Ondansetron 39 775 (1.70%) 356 777 (15.23%) 255 825 (10.92%) 167 490 (7.15%) 90 549 (3.87%) 29 390 (1.25%)
Palonosetron 26 (0.00%) 101 (0.00%) 16 (0.00%) 55 (0.00%) 74 (0.00%) 2 (0.00%)
Prochlorperazine 3173 (0.14%) 16 500 (0.70%) 10 263 (0.44%) 6070 (0.26%) 2719 (0.12%) 185 (0.01%)
Promethazine 37 115 (1.58%) 240 748 (10.28%) 158 275 (6.76%) 92 380 (3.94%) 63 774 (2.72%) 13 266 (0.57%)
1Not all Mini-Sentinel data partners contributed data for the entire study period; 2015 represents partial year of data.
2All formulations included (injectable, oral, rectal).
3Approved in 2013.
4Total number of pregnancies is lower for third trimester exposure because some live births occurred in late the second trimester.
Figure 1. Utilization of antiemetic drugs among live birth pregnancies, by calendar year, in the Mini-Sentinel Distributed Database, 2001–2014a,b
[Color figure can be viewed at wileyonlinelibrary.com]
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beginning in 2006 (26 generic applications approved
for the oral formulation and 35 applications for the
injectable formulation between 2006 and 2015), which
may have lowered the cost of ondansetron as well as
the potential for relaxed prior authorization policies
for reimbursement when prescribed during pregnancy
in some health care systems.
Despite the increase in ondansetron utilization,
safety and efficacy in pregnancy have not been
established. The effective nature of ondansetron
for NV post-chemotherapy and radiotherapy has likely
facilitated frequent use of this product for NVP; how-
ever, ondansetron is not FDA approved for NVP.
Ondansetron’s safety profile for NVP in the post-
marketing setting is conflicting. Two population-based
studies have reported positive associations between
first trimester ondansetron exposure and cleft palate4
and cardiac anomalies5, while three other studies10–12
found no increase in congenital anomalies. The totality
of these studies is not sufficient for definitive conclu-
sions on fetal safety of ondansetron in pregnancy.
A major strength of this analysis is the large
number of pregnancies identified to assess medication
use. The study population was geographically and
demographically diverse. One limitation is that
antiemetic use was based on pharmacy dispensing data
and not actual use; thus, compliance with oral formula-
tions cannot be assessed. Moreover, because we were
unable to capture inpatient oral use of ondansetron in
our analysis, total inpatient use of ondansetron during
pregnancy may be under-captured which could under-
estimate the overall use. We cannot confirm whether
other precipitating factors, such as gastrointestinal
conditions or a history of dehydration, contributed to
the decision to prescribe ondansetron. There may have
been misclassification of timing of exposure due to
estimation of gestational age, although previous stud-
ies have demonstrated that claims-based algorithms
to obtain gestational age among live births are gener-
ally valid.8 Also, the study population was limited to
predominantly commercially insured women with a
live birth delivery; thus, we cannot generalize results
to publically insured women as well as to pregnancies
not ending in live birth. Finally, we cannot measure
whether characteristics of women in the included data
partners changed over time, whether formularies
changed over time, or whether either of these impacted
the utilization curves. However, this would not be
expected to greatly affect the trend post 2009 given
that nearly all data partners contributed.
The American College of Obstetricians and
Gynecologists recommends doxylamine/pyridoxine
as first-line pharmacotherapy for NVP.13 Early
treatment is recommended to prevent progression to
hyperemesis gravidarum. Our data show, in current
practice, nearly one-quarter of insured women in
Mini-Sentinel received ondansetron during pregnancy,
with most usage consisting of oral administration.
Given the widespread use of ondansetron in
pregnancy, a great need exists for data establishing
its efficacy as well as methodologically rigorous
post-marketing assessments to evaluate its safety in
pregnant women.
KEY POINTS
• Ondansetron use in pregnancy increased mark-
edly over the study period to nearly one in four
pregnancies in 2014.
• This off-label use continues despite the approval
of another antiemetic for nausea and vomiting in
pregnancy and questions surrounding the fetal
safety of ondansetron.
• Given the widespread use of ondansetron in
pregnancy, a great need exists for rigorous post-
marketing studies evaluating its safety during
pregnancy.
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